Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
Rhea-AI Summary
Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Shalabh Gupta, M.D. will take part in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 1:30 p.m. ET.
According to the company, a live webcast and archived replay will be available via the Unicycive investor website under Events and Presentations. Investors seeking 1x1 meetings should contact their Guggenheim conference representative.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
UNCY was up 7.29% while key biotech peers were mostly negative: VANI -6.04%, ATHE -5.60%, CVM -3.68%, OSTX -0.70%, with only ANEB modestly positive at +1.06%, indicating stock-specific strength rather than a sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Regulatory milestone | Positive | -5.0% | FDA acceptance of resubmitted NDA for OLC with set PDUFA date. |
| Dec 29 | Regulatory update | Positive | -2.3% | Resubmission of NDA for OLC and expectations for new PDUFA timing. |
| Nov 25 | Investor conferences | Neutral | +3.6% | Announcement of December investor events and webcast access. |
| Nov 12 | Earnings and update | Positive | +7.3% | Q3 2025 results, OLC progress, and cash runway into 2027. |
| Nov 03 | Investor conference | Neutral | -6.5% | Planned fireside chat at Guggenheim healthcare innovation conference. |
News often shows divergence between headline tone and price: 4 of the last 5 events saw price reactions that did not clearly align with generally positive or neutral disclosures, including regulatory milestones and conference participation.
Over the last few months, UNCY has focused on advancing oxylanthanum carbonate (OLC) and engaging investors. Regulatory milestones included NDA resubmission on Dec 29, 2025 and FDA acceptance with a Jun 27, 2026 PDUFA date on Jan 29, 2026, both followed by modest declines. An earnings update on Nov 12, 2025 highlighting cash runway into 2027 coincided with a 7.31% gain. Prior Guggenheim and other conference appearances produced mixed reactions, showing that investor events can move the stock but not consistently in one direction.
Market Pulse Summary
This announcement highlights continued investor outreach via a fireside chat at a Guggenheim biotech summit on Feb 11, 2026. In recent months, UNCY combined similar conference visibility with key regulatory milestones for oxylanthanum carbonate and disclosures of increased cash resources. Investors tracking the story may focus more on upcoming PDUFA timing and subsequent business updates, while viewing conference participation as incremental support for visibility rather than a fundamental catalyst on its own.
AI-generated analysis. Not financial advice.
LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Guggenheim conference representative.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When will Unicycive (UNCY) present at the Guggenheim Emerging Outlook: Biotech Summit?
How can investors watch the UNCY fireside chat webcast and replay?
How do I schedule a 1x1 meeting with Unicycive management at the Guggenheim summit (UNCY)?
Will CEO Shalabh Gupta discuss Unicycive's clinical programs during the February 11, 2026 UNCY fireside chat?
